Skip to main content
. 2020 Feb 3;12:100212. doi: 10.1016/j.ynstr.2020.100212

Fig. 6.

Fig. 6

In an integrated dataset from three double-blind, randomized, placebo-controlled trials of brexanolone injection, brexanolone injection 90 μg/kg/h (BRX90) was associated with statistically significant improvement in depressive symptoms versus placebo from the Hour 60 primary endpoint through Day 30. *p < 0.05 versus placebo; secondary endpoints were not adjusted for multiplicity.